Elkedonia, a biotech company pioneering a novel neuroplastogen approach to develop therapeutics for severe depression and other neuropsychiatric conditions, has appointed pharmaceutical and biotech executive Pierre d’Epenoux as Independent Chairman to its Board of Directors. With a distinguished career of 30 years in the biopharmaceutical industry, d’Epenoux brings extensive experience in bringing therapeutic innovations to patients.
Leadership Experience
Most recently, d’Epenoux served as Chief Executive Officer of ImCheck Therapeutics, which he led through strategic partnerships and transactions, culminating in its acquisition by Ipsen in 2025. Throughout his career, he has built deep expertise in biotech-pharma licensing agreements, strategic transactions and partnerships. Delphine Charvin, Chief Executive Officer and cofounder of Elkedonia, said welcoming d’Epenoux as Chairman brings “a highly complementary skill set to the Board—his extensive experience in biotech-pharma partnerships, licensing and transactions will be invaluable as we strengthen our strategic positioning and build long-term value.”
Elkedonia’s Mission
Elkedonia is advancing its lead discovery program targeting the inhibition of the intracellular ELK1 protein. While this transcription factor was previously thought to be undruggable, Elkedonia’s novel chemistry targets it to restore neuroplasticity without the hallucinogenic or dissociative side effects of psychedelics or ketamine derivatives. Major depressive disorder affects 332 million people worldwide—25 million each in the United States and Europe. One-third of patients affected by MDD do not respond adequately to existing treatments, a condition defined as treatment-resistant depression.
The company was founded in 2025 and raised €11.25 million in seed financing, backed by a syndicate of leading European life sciences investors, including Kurma Partners, WE Ventures, Bpifrance, Angelini Ventures, Carma Fund, Capital Grand Est, Argobio and Sambrinvest.
This article is an AI-assisted summary. All facts and figures are drawn from the original report: https://www.financialcontent.com/article/gnwcq-2026-4-22-elkedonia-strengthens-board-of-directors-with-appointment-of-pierre-depenoux-as-independent-chairman